Orlistat  reduced body weight ( weighted mean difference : −2.12 , p < 0.001 ) , total‐cholesterol ( weighted mean difference : −0.30 mmol/L , p < 0.001 ) , low‐density lipoprotein cholesterol ( weighted mean difference : −0.27 mmol/L , p < 0.001 ) , high‐density lipoprotein cholesterol ( weighted mean difference : −0.034 mmol/L , p < 0.001 ) and triglyceride ( weighted mean difference : −0.09 mmol/L , p < 0.001 ) concentrations , while no effect on lipoprotein(a ) was observed .
Total‐ and low‐density lipoprotein cholesterol‐lowering were associated negatively with duration of orlistat treatment and positively with body weight changes .
In conclusion , Orlistat treatment slightly reduces cholesterol and triglyceride levels , but not lipoprotein(a ) levels .
Total‐ and low‐density lipoprotein cholesterol levels reductions are more consistent in patients with greater body weight reduction and shorter duration of orlistat treatment .
We investigated the efficacy of orlistat on plasma lipids and body weight in a meta‐ analysis of 33 studies including 9732  participants .Orlistat  was associated with a slight but significant decrease in body weight , plasma cholesterol and triglyceride concentrations , whereas plasma Lp(a ) levels were not affected by orlistat treatment .
Greater body weight reduction and lower duration of orlistat treatment promoted more consistent plasma total‐ and LDL‐cholesterol lowering
& NA ; Orlistat , an inhibitor of intestinal lipase , promotes body weight reduction .
The lipid‐lowering efficacy of orlistat is controversial and the effect of orlistat‐induced body weight reduction on lipid changes has not been explored in meta‐regression analyses .
HighlightsOrlistat is an inhibitor of intestinal lipase promoting body weight reduction , but whose lipid‐lowering efficacy is controversial .
Effects of orlistat on obesity-related diseases - a six-month randomized trial.
AIM To assess the effect of orlistat on body weight and concomitant diseases in patients with body mass index ( BMI ) of > 28 kg/m2 and poorly controlled type 2 diabetes , hypertension or hypercholesterolaemia . METHODS This trial was a six-month , r and omized , double-blind , placebo-controlled study of orlistat 120 mg three times daily plus a mildly reduced-calorie diet .  1004 obese patients ( BMI 28 - 40 kg/m2 ) were included by 253 private endocrinologists and received orlistat ( n = 499 ) or placebo ( n = 505 ) . Patients were stratified by concomitant disorder ( type 2 diabetes , n = 193 ; hypertension , n = 614 ; hypercholesterolaemia , n = 197 ) . Body weight , anthropometry , lipid and glycaemic control parameters and blood pressure . RESULTS After six months , orlistat produced a significantly greater weight loss than placebo in type 2 diabetes ( -4.2 % vs. -1.4 % ) , hypertension ( -6.2 % vs. -1.9 % ) and hypercholesterolaemia ( -5.5 % vs. -2.3 % ) groups ( p < 0.0001 for all ) . There was a greater decrease in HbA(1c ) in the type 2 diabetes group ( -0.54 vs. -0.18 % ; p = 0.002 ) and low-density lipoprotein (LDL)-cholesterol in the hypercholesterolaemia group ( -11.7 % vs. -4.5 % ; p = 0.004 ) with orlistat vs. placebo .  Early weight loss ( > or = 5 % at 12 weeks ) was associated with the highest weight loss in each group , and the highest decreases in HbA1c , LDL-cholesterol and diastolic blood pressure in patients with type 2 diabetes , hypercholesterolaemia and hypertension , respectively , at six months . The incidence of adverse events was similar for orlistat and placebo , except for certain generally well-tolerated gastrointestinal events that were more common with orlistat . CONCLUSION Orlistat plus a mildly reduced-calorie diet produced clinical ly meaningful weight loss and improvements in risk factors in overweight and obese patients with poorly controlled type 2 diabetes , hypertension or hypercholesterolaemia
Orlistat  reduced body weight ( weighted mean difference : −2.12 , p < 0.001 ) , total‐cholesterol ( weighted mean difference : −0.30 mmol/L , p < 0.001 ) , low‐density lipoprotein cholesterol ( weighted mean difference : −0.27 mmol/L , p < 0.001 ) , high‐density lipoprotein cholesterol ( weighted mean difference : −0.034 mmol/L , p < 0.001 ) and triglyceride ( weighted mean difference : −0.09 mmol/L , p < 0.001 ) concentrations , while no effect on lipoprotein(a ) was observed .
Total‐ and low‐density lipoprotein cholesterol‐lowering were associated negatively with duration of orlistat treatment and positively with body weight changes .
In conclusion , Orlistat treatment slightly reduces cholesterol and triglyceride levels , but not lipoprotein(a ) levels .
Total‐ and low‐density lipoprotein cholesterol levels reductions are more consistent in patients with greater body weight reduction and shorter duration of orlistat treatment .
We investigated the efficacy of orlistat on plasma lipids and body weight in a meta‐ analysis of 33 studies including 9732  participants .Orlistat  was associated with a slight but significant decrease in body weight , plasma cholesterol and triglyceride concentrations , whereas plasma Lp(a ) levels were not affected by orlistat treatment .
Greater body weight reduction and lower duration of orlistat treatment promoted more consistent plasma total‐ and LDL‐cholesterol lowering
& NA ; Orlistat , an inhibitor of intestinal lipase , promotes body weight reduction .
The lipid‐lowering efficacy of orlistat is controversial and the effect of orlistat‐induced body weight reduction on lipid changes has not been explored in meta‐regression analyses .
HighlightsOrlistat is an inhibitor of intestinal lipase promoting body weight reduction , but whose lipid‐lowering efficacy is controversial .